Evidence map›Paper›PMID 21753120›Full record

ArticleScience translational medicine2011

Drug effectiveness explained: the mathematics of antiviral agents for HIV.

Alan S Perelson, Steven G Deeks

Abstract readComment
In one paragraph

Article in Science translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alan S PerelsonLos Alamos National Laboratory, Los Alamos, NM 87501, USA. asp@lanl.gov
Steven G Deeks
San Francisco General Hospital · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
UNM COBRE: THEORETICAL STUDY OF SPECIFICITY OF RNA SILENCING MECHANISMP20RR018754 · NCRR · UNIVERSITY OF NEW MEXICO · PI ADEMA, COENRAAD M · 2003 to 2011
$16.7M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
COBRE Center for Evolutionary and Theoretical ImmunologyP20GM103452 · NIGMS · UNIVERSITY OF NEW MEXICO · PI LOKER, ERIC SAMUEL · 2012 to 2013
$4.2M
MODELING VIRAL AND T LYMPHOCYTE DYNAMICSR01RR006555 · NCRR · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1991 to 2011
$3.9M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Immune System Modeling/HIVR37AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 2002 to 2011
$2.4M
The impact of early antiretroviral therapy on HIV persistence and inflammationR01AI087145 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2009 to 2010
$1.6M
Preventing the Establishment of Enfuvirtide-resistance in the Latent ReservoirK24AI069994 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2007 to 2016
$1.5M
NCRR NIH HHS P20 RR018754NCRR NIH HHS R01 RR006555NIAID NIH HHS K24 AI069994NIAID NIH HHS K24AI069994NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI028433NIAID NIH HHS R01 AI087145NIAID NIH HHS R37 AI028433NIGMS NIH HHS P20 GM103452NIH HHS R01 OD011095
6 · The paper itself

Abstract

Antiretroviral therapy has improved the quality and length of life of millions of individuals affected by human immunodeficiency virus type 1 (HIV-1). The capacity of these drugs to indefinitely suppress HIV-which has a well-known capacity for escaping antiviral pressures-is surprising. In this issue of Science Translational Medicine, Shen et al. use a combination of mathematical modeling and experiment to examine the potency of anti-HIV drugs. They show that non-nucleoside reverse transcriptase inhibitors and protease inhibitors exhibit cooperative dose-response curves-a finding that has implications for the treatment of HIV as well as other viral infections, such as hepatitis C.

Indexed as

Models, BiologicalAnti-HIV AgentsHIVAnti-HIV Agents

Identifiers

PMID21753120
PMCPMC3236558
OpenAlexW2112198714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.